We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
In December 2014, Steve Daly joined Adocia in the newly created role of United States General Manager. Adocia is a clinical-stage, French biotech focused on affordable innovation by unlocking novel clinical attributes of already-approved peptides and proteins. Aside from day- to-day operations at Adocia USA, Steve is responsible, in whole or in part, for Business Development, Investor Relations, and Scientific Community Engagement. Before joining Adocia, Steve served in senior roles for the commercialization of therapeutics in the diabetes and metabolism fields at companies such as Amylin Pharmaceuticals (exenatide, pramlintide), Halozyme (hyaluronidase), and Affymax (peginesatide). Prior to nearly 14 years of experience in diabetes and metabolism, Steve held portfolio planning and commercialization roles in the generic and biosimilar marketplace for Baxter International and Sicor, a division of Teva Pharmaceuticals.
This speaker's sessions: